Omega-3 polyunsaturated acids

Pharmacological properties

omega-3 polyunsaturated fatty acids - eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) - are essential fatty acids. the drug actively affects blood plasma lipids, reducing the level of Tg, LDL and VLDL. the drug affects hemostasis and reduces the risk of thrombosis due to the effect on platelet aggregation ability; moderately reduces hell. The normalization of the blood lipid spectrum also occurs due to a decrease in the synthesis of tg in the liver, since EPA and DHA inhibit the esterification of other fatty acids, as well as by reducing the amount of free fatty acids (the number of β-oxidation of fatty acids peroxisome increases) involved in the synthesis of tg. a decrease in Tg synthesis leads to a decrease in the level of VLDL

α-Tocopherol is an antioxidant that prevents the oxidation of polyunsaturated fatty acids.

Pharmacokinetics There are no data on pharmacokinetics.

Indications

For the primary prevention of atherosclerosis and cardiovascular disease; as part of the complex therapy of atherosclerosis, coronary heart disease, ag; with the secondary prevention of myocardial infarction in addition to standard methods of treatment (for example, statins, antiplatelet agents, β-adrenergic blockers, apf inhibitors); with hypertriglyceridemia in addition to diet therapy, if the latter is not effective enough.

Application

The drug is taken with meals.

For the purpose of prevention, adults and children over the age of 12 are prescribed 1 capsule per day. According to individual indications, the dose of the drug can be increased to 2 capsules per day.

In the complex therapy of cardiovascular diseases - 2 capsules per day.

With hypertriglyceridemia, the initial dose is 2 capsules per day (in 1 or 2 doses). In case of insufficient effect, the dose of the drug is increased to 4 capsules per day. Treatment must be continued until the desired therapeutic effect is achieved.

Contraindications

Increased individual sensitivity to any of the components of the drug. exacerbation of chronic cholecystitis and chronic pancreatitis, exacerbation of diseases of the hepatobiliary system, gallstone disease, pathological conditions accompanied by hemorrhagic syndrome.

Side effects

From the immune system: hypersensitivity reactions.

From the side of metabolism and nutrition: hyperglycemia.

From the nervous system: dizziness, dysgeusia, headache.

Vascular disorders: arterial hypotension.

From the blood system and lymphatic system: hemorrhagic diathesis.

From the respiratory system, chest and mediastinal organs: dry nasal mucosa.

From the gastrointestinal tract: dyspeptic disorders, nausea, abdominal pain, gastrointestinal disorders (gastroesophageal reflux, belching, vomiting, flatulence, diarrhea, constipation), gastritis, gastroenteritis, bleeding from the lower digestive tract.

From the hepatobiliary system: impaired liver function.

On the part of the skin and subcutaneous tissues: skin rash, itching, redness of the skin, urticaria, acne.

Laboratory indicators: an increase in the number of leukocytes, LDH levels in the blood, an increase in the activity of transaminases.

special instructions

In the case of a moderate increase in bleeding time (when using the drug in high doses, that is, 4 capsules per day), it is necessary to monitor the condition of patients receiving anticoagulant therapy, and, if necessary, adjust the dose of anticoagulant accordingly. it is necessary to take into account the possibility of increasing bleeding time in patients with an increased risk of hemorrhage (due to severe injury, surgery or other reasons).

A drug should not be prescribed for the treatment of exogenous hypertriglyceridemia (type I hyperchylomicronemia).

In patients with liver failure (especially when taking the drug in high doses), regular monitoring of liver function (AlAT and AsAT) is necessary.

The likelihood of side effects decreases with the use of the drug with food.

Use during pregnancy and lactation. The use of the drug during pregnancy is possible only as directed by the doctor, taking into account the risk / benefit ratio. During breastfeeding, the drug can be used after consulting a doctor.

The ability to influence the reaction rate when driving vehicles or working with other mechanisms. Does not affect.

Children. Due to the lack of data on efficacy and safety, the drug is not used in children under the age of 12 years.

Interactions

It is not recommended to prescribe in combination with fibrates due to the lack of clinical experience. the appointment of epadol-neo simultaneously with warfarin does not lead to hemorrhagic complications, however, in the case of combined use of these drugs or termination of treatment with epadol-neo, prothrombin time should be monitored.

Overdose

In case of an overdose, allergic reactions can be noted, similar to those that are detected with a side effect. treatment: symptomatic therapy.

Storage conditions

In the original packaging at a temperature not exceeding 25 ° C.